10-K Decoder · All companies

Immunovant, Inc.

IMVT · FY2026 · Fiscal year ended Mar 31, 2026 · 10-K filed May 2026

Open the dashboardInfographicSummary

FY2026 key figures

$FY2026FY2025Change
Revenue$0K$0K
Operating income−$533M−$438M−21.6%
Net income−$506M−$414M−22.2%

Latest quarter: Q2 FY2027

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 9, 2026

$Q2 FY2027Year earlierChange
Revenue$0K$0K
Operating income−$97.2M−$126M+22.8%
Net income−$97.2M−$126M+23.2%

Q2 FY2027 dashboardQ2 FY2027 infographic

Questions

What was Immunovant's revenue in FY2026?
$0K in FY2026 (Fiscal year ended Mar 31, 2026), no comparable figure vs $0K a year earlier, per its 10-K filed May 2026.
Was Immunovant profitable in FY2026?
No: net income was −$506M and operating income −$533M in FY2026.
What was Immunovant's revenue in Q2 FY2027?
$0K (n/a vs a year earlier), per its Form 10-Q filed Nov 9, 2026.